Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
暂无分享,去创建一个
J. Lisziewicz | H. Jessen | F. Lori | M. Wainberg | R. Maserati | A. Foli | A. Malykh | R. Gallo | L. Minoli | A. De Antoni | E. Barchi | A. D. Degli Antoni | D. Padrini | Andrei G. Malykh | Andrea Foli | Franco Lori | Renato Maserati | M. A. Wainberg | Robert C. Gallo | Heiko Jessen | Anna De Antoni | Lorenzo Minoli | Daniela Padrini | Annamaria Degli Antoni | Enrico Barchi | Robert C. Gallo
[1] J. Montaner,et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. , 1997, The Journal of infectious diseases.
[2] B. Clotet,et al. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea. , 1996, Antiviral therapy.
[3] F. Biron,et al. 1–year follow-up of the use of hydroxycarbamide and didanosine in HIV infection , 1996, The Lancet.
[4] Marc Parmentier,et al. A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.
[5] Ying Sun,et al. The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.
[6] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[7] F. Lori,et al. Pharmacokinetics of Hydroxyurea in Patients Infected with Human Immunodeficiency Virus Type I , 1996, Journal of clinical pharmacology.
[8] D. Kuritzkes,et al. Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .
[9] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.
[10] F. Lori,et al. Hydroxyurea and AIDS: an old drug finds a new application? , 1995, AIDS research and human retroviruses.
[11] S D Kemp,et al. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.
[12] D. Richman,et al. Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy , 1995, Annals of Internal Medicine.
[13] J. Grange,et al. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[14] J N Weinstein,et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. , 1994, Science.
[15] M A Wainberg,et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine , 1994, Antimicrobial Agents and Chemotherapy.
[16] F. Lori,et al. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[17] D. Richman. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents , 1993, Antimicrobial Agents and Chemotherapy.
[18] J. Singer,et al. Clinical correlates of in vitro HIV‐1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial , 1993, AIDS.
[19] E. Walter,et al. HIV-1 sensitivity to zidovudine and clinical outcome in children , 1992, The Lancet.
[20] S D Kemp,et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.
[21] S. Broder,et al. Pharmacokinetics of 2′, 3′‐dideoxyadenosine and 2′, 3′‐dideoxyinosine in patients with severe human immunodeficiency virus infection , 1990, Clinical pharmacology and therapeutics.
[22] D G Altman,et al. Analysis of serial measurements in medical research. , 1990, BMJ.